John A. Josey - Jun 1, 2021 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Director
Signature
/s/ Charles N. York, II, as Attorney-in-Fact for Reporting Person
Stock symbol
DAWN
Transactions as of
Jun 1, 2021
Transactions value $
$112,000
Form type
4
Date filed
6/1/2021, 09:51 PM
Previous filing
May 26, 2021
Next filing
Jun 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Purchase $112K +7K +10.72% $16.00 72.3K Jun 1, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Stock Option (right to buy Common Stock) Award $0 +63K $0.00 63K May 26, 2021 Common Stock 63K $16.00 Direct F2, F3
transaction DAWN Stock Option (right to buy Common Stock) Award $0 +1.18K $0.00 1.18K May 26, 2021 Common Stock 1.18K $16.00 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Certain of the shares are subject to the Issuer's right of repurchase if underlying vesting conditions are not met.
F2 The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on June 26, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3 The Reporting Person is reporting the acquisition of these securities pursuant to Rule 16a-2(a) of the Exchange Act.
F4 The option vests as to 1/48th of the total shares on each monthly anniversary, beginning on November 6, 2020, subject to the Reporting Person's provision of service to the Issuer on each vesting date.